Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-3-30
pubmed:abstractText
Hypoxia-inducible factor-1alpha (HIF-1alpha) regulates cellular responses to hypoxia and is rapidly degraded under normoxia through von Hippel-Lindau (VHL) mediated ubiquitination. Although HIF-1alpha stabilization appears to be the molecular basis for VHL-associated cancers, stabilizing mutations in HIF-1alpha have not been reported.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0270-4137
pubmed:author
pubmed:copyrightInfo
(c) 2004 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
215-21
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15538748-Biopsy, pubmed-meshheading:15538748-Bone Marrow, pubmed-meshheading:15538748-Cell Line, pubmed-meshheading:15538748-DNA, Neoplasm, pubmed-meshheading:15538748-Genetic Predisposition to Disease, pubmed-meshheading:15538748-Humans, pubmed-meshheading:15538748-Hypoxia-Inducible Factor 1, alpha Subunit, pubmed-meshheading:15538748-Luciferases, pubmed-meshheading:15538748-Male, pubmed-meshheading:15538748-Mixed Function Oxygenases, pubmed-meshheading:15538748-Mutagenesis, Site-Directed, pubmed-meshheading:15538748-Mutation, pubmed-meshheading:15538748-Oxygen, pubmed-meshheading:15538748-Polymerase Chain Reaction, pubmed-meshheading:15538748-Prostatic Neoplasms, pubmed-meshheading:15538748-Recombinant Fusion Proteins, pubmed-meshheading:15538748-Sequence Analysis, DNA, pubmed-meshheading:15538748-Transcription, Genetic, pubmed-meshheading:15538748-Transcription Factors, pubmed-meshheading:15538748-Transfection
pubmed:year
2005
pubmed:articleTitle
Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.
pubmed:affiliation
Cancer Biology Program, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't